Navigation Links
Nutraceutical Reports Fiscal 2008 Q1 Results
Date:1/31/2008

copies of which are available upon request from our investor relations group or which may be obtained at the SEC's website (http://www.sec.gov).

NUTRACEUTICAL INTERNATIONAL CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(unaudited; dollars in thousands)

December 31, September 30,

2007 2007

Assets

Current assets, net $49,904 $51,534

Property, plant and equipment, net 42,367 39,506

Goodwill 39,066 38,978

Other non-current assets, net 15,898 16,384

$147,235 $146,402

Liabilities and Stockholders' Equity

Current liabilities $17,725 $20,275

Long-term liabilities 21,227 20,208

Stockholders' equity 108,283 105,919

$147,235 $146,402

NUTRACEUTICAL INTERNATIONAL CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited; dollars in thousands, except per share data)

Three months ended December 31,

2007 2006

Net sales $41,086 $35,848

Cost of sales 18,773 16,324

Gross profit 22,313 19,524

Operating expenses

Selling, general and administrative 16,628 13,922

<
'/>"/>
SOURCE Nutraceutical International Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Neurochem appoints Mr. Gary Schmid as CEO of new nutraceutical business
2. NutraCea Forms Joint Ventures With HerbalScience to Develop Nutraceutical Extracts and Pharmaceutical Chemistries From Stabilized Rice Bran
3. Nutraceutical Reports 2007 Fiscal Year End Results
4. New Nutraceutical Supplement Provides Simplified Approach to Diabetes Management Programs
5. New Nutraceutical That Stabilizes Blood Sugar Naturally is Introduced
6. Matrixx Initiatives, Inc. Reports Fiscal 3rd Quarter Net Sales of $30.8 Million and Net Loss of ($0.07) Per Share
7. Accuray Reports Continued Growth in Second Quarter of Fiscal 2008
8. Cardinal Health Reports Second Quarter Results, Revises EPS Outlook
9. Encision Reports Third Fiscal Quarter Results
10. Zimmer Reports Fourth Quarter and 2007 Financial Results
11. Amylin Pharmaceuticals Reports 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/26/2014)... FL (PRWEB) December 26, 2014 India ... health insurance in the USA, announced today a new ... assist members in choosing the right plan for their ... the complexity out of the selection process when choosing ... by age group with only a few clicks. Many ...
(Date:12/25/2014)... The microscopy market is estimated ... reach $5,756.0 million by 2019. Optical microscopy is ... electron microscopes product segment is expected to show ... Rising focus on nanotechnology, technological advancements, and increasing ... market. , Get Full Copy of Report @ ...
(Date:12/25/2014)... Dallas, TX (PRWEB) December 26, 2014 ... Analysis to 2023” focuses on the current treatment landscape, ... colorectal cancer market. TS-1 is an anti-cancer drug which ... administered orally and is also used for treating gastric ... gimestat and otastat potassium. The drug was first approved ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company ... collection of discounted prom dresses, most of which are ... of the company, the promotion is valid until Jan. ... expand the UK market. , The prom dresses in ... and styles: A-line strapless, empire strapless chiffon, one shoulder, ...
(Date:12/25/2014)... Helen Harris’ RP (Retinitis Pigmentosa) International ... after an 8 year battle with breast cancer. ... in her home in Woodland Hills California after an ... , As the founder and volunteer President ... and championed many of today's greatest breakthroughs in restoring ...
Breaking Medicine News(10 mins):Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4
... Autism spectrum disorder (ASD) is a ... has strong genetic underpinnings, it is also a mix ... many medical disorders and syndromes, the nature of such ... one in 150 children suffers from ASD, and it,s ...
... cj Advertising,s employees lend a hand to the Arthritis Foundation, fellow ... ... -- Nashville-based cj Advertising and its charity fundraising initiative, Camels ... helping raise funds for the Arthritis Foundation and fund research toward ...
... provider, announced that it has acquired Key Instruments, Inc. Terms ... flow meter manufacturer based in Trevose, PA which offers precision ... flow meters, electronic flow meters, and flow control valves for ... ...
... method of accelerated tissue healing is showing its worth in soft-tissue repair, ... ... It was first used by dental surgeons about 15 years ago to ... Rich Plasma (PRP) therapy is today being applied in Singapore as ...
... President Al Gore Endorses Trans-Pacific Collaboration to Promote Use ... Cell-Based TherapiesSOUTH SAN FRANCISCO, Calif., and KYOTO, Japan, April ... for iPS Cell Research and Application (CiRA), today ... basic research, development and application of induced pluripotent stem ...
... BlackBerry® is a Microsoft licensed solution to allow BlackBerry® devices ... for BlackBerry® solution is ideal for organisations or businesses that ... Microsoft Exchange Server, Kerio MailServer, Zimbra Collaboration Suite or the ... ...
Cached Medicine News:Health News:Occupational Therapists Use Sensory Integration to Help Autistic Children Find Fitting Social Behaviors 2Health News:Occupational Therapists Use Sensory Integration to Help Autistic Children Find Fitting Social Behaviors 3Health News:Camels with a Cause Helps Ease the Pain of Arthritis 2Health News:Camels with a Cause Helps Ease the Pain of Arthritis 3Health News:Camels with a Cause Helps Ease the Pain of Arthritis 4Health News:Brooks Instrument Acquires Flow Products Supplier Key Instruments 2Health News:Singapore First in Southeast Asia to Use Novel Treatment for Sports and Musculoskeletal Injuries 2Health News:Singapore First in Southeast Asia to Use Novel Treatment for Sports and Musculoskeletal Injuries 3Health News:Singapore First in Southeast Asia to Use Novel Treatment for Sports and Musculoskeletal Injuries 4Health News:iZumi Bio and Kyoto University Form Collaboration to Advance Induced Pluripotent Stem Cell Technology 2Health News:iZumi Bio and Kyoto University Form Collaboration to Advance Induced Pluripotent Stem Cell Technology 3Health News:iZumi Bio and Kyoto University Form Collaboration to Advance Induced Pluripotent Stem Cell Technology 4Health News:iZumi Bio and Kyoto University Form Collaboration to Advance Induced Pluripotent Stem Cell Technology 5Health News:NotifySync&#8482; Provides BlackBerry a Direct Connection to Any Email Platform Supporting Microsoft ActiveSync 2
(Date:12/24/2014)... -- Actavis plc (NYSE: ACT ) today ... response letter from the U.S. Food and Drug ... for the fixed-dose combination (FDC) of nebivolol and ... Photo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO ... a complete response letter, Actavis remains committed to ...
(Date:12/24/2014)... N.J. , Dec. 24, 2014 ... a late-stage biopharmaceutical company developing products that address ... oncology and biodefense, announced today that on December ... public offering. The Company raised approximately ... and intends to use the net proceeds from ...
(Date:12/24/2014)... and FARMINGTON, Conn. , ... (NYSE MKT: PTN), a biopharmaceutical company developing targeted, ... with significant unmet medical need and commercial potential, ... private placement of 2,050,000 shares of its common ... shares of its common stock.  Funds under the ...
Breaking Medicine Technology:Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4
... HIGHLIGHTS :2012 Results (all percentages are to comparable periods ... 5% to $665 million, a new quarterly high. Q1 sales grew ... growth of 4% and 1%, respectively.  Acquisitions contributed 4% to sales ... sales by 2%. , Q1 2012 reported diluted ...
... LAKE SUCCESS, N.Y., April 24, 2012  Polar ( www.polarusa.com ... training technology, today announced the appointment of Herb Baer ... role, Baer will be responsible for the overall direction ... of the business including consumer fitness, running, cycling, physical ...
Cached Medicine Technology:Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 2Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 3Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 4Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 5Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 6Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 7Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 8Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 9Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 10Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 11Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 12Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 13Herb Baer Appointed President of Polar USA 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: